You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Indolent Lymphoma

Showing 51 - 75 of 5,238
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent DLBCL Activated B-Cell Type, Recurrent DLBCL Germinal Center B-Cell Type, Recurrent High Grade B-Cell Lymphoma With

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type
  • +8 more
  • Biospecimen Collection
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Mar 8, 2023

DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to DLBCL Trial

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • +2 more
  • Biospecimen Collection
  • +5 more
  • (no location specified)
Sep 5, 2023

Indolent B-cell Non-Hodgkin's Lymphoma Trial in Japan (ME-401)

Active, not recruiting
  • Indolent B-cell Non-Hodgkin's Lymphoma
  • Anjo, Aichi, Japan
  • +29 more
Dec 10, 2021

CLL/SLL, NHL, Mantle Cell Lymphoma Trial in United States (SYNCAR-001, STK-009, Cyclophosphamide)

Recruiting
  • CLL/SLL
  • +6 more
  • Duarte, California
  • +4 more
Jan 12, 2023

Lymphoma Non-Hodgkin Trial in Japan (Copanlisib (BAY80-6946))

Completed
  • Lymphoma Non-Hodgkin
  • Copanlisib (BAY80-6946)
  • Nagoya, Aichi, Japan
  • +12 more
Feb 21, 2022

Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Mantle-Cell Trial in Providence (Rituximab, Bendamustine, Vincristine

Active, not recruiting
  • Lymphoma, Non-Hodgkin
  • +5 more
  • Providence, Rhode Island
    Rhode Island Hospital and The Miriam Hospital
Jul 19, 2021

Leukemia Trial in New York (therapeutic autologous lymphocytes, cyclophosphamide)

Active, not recruiting
  • Leukemia
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Nov 18, 2021

Recurrent DLBCL, Recurrent DLBCL, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma Trial in Seattle

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Dec 30, 2022

Non-Hodgkin's Lymphoma Trial in Japan (bendamustine HCl)

Completed
  • Non-Hodgkin's Lymphoma
  • bendamustine hydrochloride
  • Kanagawa, Japan
  • +3 more
Oct 19, 2020

Lymphoma, Non-Hodgkin Trial in Worldwide (Fludarabine, Cyclophosphamide, JCAR017)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Santa Monica, California
  • +36 more
Jan 25, 2023

Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin Trial in France, Italy, Netherlands (Obinutuzumab, CC-122)

Active, not recruiting
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, Non-Hodgkin
  • Borddeaux Cedex, France
  • +9 more
Nov 11, 2022

T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia Trial in United States (Optional Blood Sample, Optional Nail

Recruiting
  • T-cell Lymphoma
  • +30 more
  • Optional Blood Sample
  • Optional Nail Sample
  • Duarte, California
  • +25 more
Jul 28, 2023

Mantle Cell Lymphoma Trial in Spain (IBRUTINIB, Rituximab)

Active, not recruiting
  • Mantle Cell Lymphoma
  • Terrassa, Barcelona, Spain
  • +14 more
Nov 3, 2021

Non Hodgkin Lymphoma Trial in Australia, United States (Tenalisib,)

Completed
Has Results
  • Non Hodgkin Lymphoma
  • Huntsville, Alabama
  • +11 more
Jul 20, 2021

Mantle Cell Lymphoma, Follicular Lymphoma, Splenic Marginal Zone Lymphoma Trial in Chapel Hill (CAR.k.28, Fludarabine,

Recruiting
  • Mantle Cell Lymphoma
  • +5 more
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Nov 19, 2021

Non-Hodgkin Lymphoma Trial in Boston (Blinatumomab)

Active, not recruiting
  • Non-Hodgkin Lymphoma
  • Boston, Massachusetts
    Massachusetts general Hospital
Jan 31, 2021

Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma Trial in United States (Duvelisib, Placebo,

Withdrawn
  • Indolent Non-Hodgkin's Lymphoma
  • +3 more
  • Plainville, Connecticut
  • +6 more
Mar 15, 2021

Follicular Lymphoma and Marginal Zone Lymphoma Trial in Beijing (Recombinant Humanized Monoclonal Antibody MIL62 Injection,

Recruiting
  • Follicular Lymphoma and Marginal Zone Lymphoma
  • Recombinant Humanized Monoclonal Antibody MIL62 Injection
  • Lenalidomide
  • Beijing, China
    Chinese Academy of Medical Sciences and Peking Union Medical Col
Jun 15, 2021

Chronic Lymphocytic Leukemia, Indolent Non-Hodgkin Lymphoma, Follicular Lymphoma Trial in Aichi, Miyagi, Tokyo (Idelalisib)

Completed
Has Results
  • Chronic Lymphocytic Leukemia
  • +5 more
  • Aichi, Japan
  • +2 more
Feb 24, 2021

Non-Hodgkin's Lymphoma, Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor

Recruiting
  • Non-Hodgkin's Lymphoma
  • +18 more
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Mar 11, 2021

Follicular Lymphoma (FL/Indolent NHL), Aggressive NHL (a NHL), Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma

Completed
Has Results
  • Follicular Lymphoma (FL/Indolent NHL)
  • +4 more
  • Huntsville, Alabama
  • +22 more
Apr 1, 2022

Melanoma, NSCLC, Breast Cancer Trial in United States (CDX-1140, CDX-301, Pembrolizumab)

Completed
  • Melanoma
  • +25 more
  • Scottsdale, Arizona
  • +10 more
Sep 27, 2022

LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous T-Cell Lymphoma - Category, Primary Cutaneous CD8-Positive

Recruiting
  • LGLL - Large Granular Lymphocytic Leukemia
  • +13 more
  • Duarte, California
  • +9 more
Aug 9, 2022

Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma Trial in United States (Rituximab, ALT-803)

Terminated
  • Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma
  • Rituximab
  • ALT-803
  • Minneapolis, Minnesota
  • +3 more
Feb 11, 2021

Indolent Non-hodgkin Lymphoma Trial in München (Obinutuzumab, Bendamustine)

Active, not recruiting
  • Indolent Non-hodgkin Lymphoma
  • München, Bavaria, Germany
    Klinikum der Universität München
Jul 23, 2021